Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review.

Author: Ran AN ¹ ; Jian HOU ²
Author Information

1. Department of Hematology,Changzheng Hospital,The Second Military Medical University,Shanghai 200003,China.
2. Department of Hematology,Changzheng Hospital,The Second Military Medical University,Shanghai 200003,China. E-mail:houjian167@sohu.com.
Publication Type:Journal Article
From: Journal of Experimental Hematology 2016;24(6):1888-1891
CountryChina
Language:Chinese
Abstract: Multiple myeloma is a plasma cell malignant clone proliferation diseases and has been remained incurable. In the resent years, the widespread application of immunomodulatory drugs (IMiD) have made a great progress in the treatment of multiple myeloma, greatly improved the complete remission rate and prolonged the overall survival of MM patients. According to recent researches, CRBN (cereblon) plays an important role in mediating anti-myeloma effects of IMiD, and its expression correlated with the effect of IMiD treatment and the prognosis of multiple myeloma. The discovery of CRBN not only deepened the understanding the molecular pharmacological mechanisms of IMiD, but also provide new insights into the novel therapeutic targets and therapeutic strategies for myeloma. This review focuses on the research advances of effectiveness and related mechanisms of CRBN and IMiD for MM, the concrete problems discussing in this review are discover of CRBN, therapeutic effect of CRBN and IMiD, mechnism of CRBN in IMiD treatment for MM, and so on.